NCT05092022 St. Joseph's HPV Self-sampling: Offering a Self-sampling Option in Clinic
| NCT ID | NCT05092022 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Milton S. Hershey Medical Center |
| Condition | Cervical Cancer Screening |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2023-09-18 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2023-09-18 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to evaluate the effectiveness of offering self-sampled human papillomavirus (HPV) tests in increasing participation in cervical cancer screening, compared to the standard of care clinician-sampled test. The primary study endpoints are (1) patients' acceptability of self-sampled HPV tests vs. clinician-sampled test, and (2) patients' completion of self-sampled HPV test. The secondary study endpoint to be measured is the increase in cervical cancer screenings of any type in the PSH St. Joseph's residency clinic patient population.
Eligibility Criteria
Inclusion Criteria: * Eligible but out-of-date for cervical cancer screening * Able to speak, read, and communicate well in English or Spanish * Not at greater than average risk for cervical cancer Exclusion Criteria: * Pregnant * Incarcerated * Greater than average risk for cervical cancer, for example: * Already diagnosed with high-grade precancerous cervical cancer or cervical lesions * Has a compromised immune system * Unable to speak, read, and communicate well in English or Spanish * Unable or unwilling to give implied consent or otherwise complete study requirements
Contact & Investigator
Christina Scartozzi, DO
PRINCIPAL INVESTIGATOR
Penn State College of Medicine
Frequently Asked Questions
Who can join the NCT05092022 clinical trial?
This trial is open to female participants only, aged 30 Years or older, up to 65 Years, studying Cervical Cancer Screening. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05092022 currently recruiting?
Yes, NCT05092022 is actively recruiting participants. Contact the research team at cscartozzi@pennstatehealth.psu.edu for enrollment information.
Where is the NCT05092022 trial being conducted?
This trial is being conducted at Reading, United States.
Who is sponsoring the NCT05092022 clinical trial?
NCT05092022 is sponsored by Milton S. Hershey Medical Center. The principal investigator is Christina Scartozzi, DO at Penn State College of Medicine. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.